ArticleMolecular therapy : the journal of the American Society of Gene Therapy2025
Orf virus-based vectors induce potent germinal center B cell, Tfh cell, and CD8
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cytolysis limits IFN-I and effector memory CD8 T cells after viral vector vaccination.Molecular therapy. Nucleic acids · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recombinant Orf virus (rORFV) vectors have proven safe and immunogenic in human clinical trials but the cellular correlates of antibody induction by this parapoxviral platform remain ill-defined. To characterize antigen-specific B cell responses at the cellular level, we performed adoptive transfer experiments with monoclonal B cells specific for the glycoproteins of either vesicular stomatitis virus or lymphocytic choriomeningitis virus. Immunizations of mice with rORFV delivering these glycoproteins stimulated antigen-specific B cells to engage in germinal center (GC) reactions and to differentiate into antibody-secreting cells and memory B cells. These responses could be recalled upon homologous rORFV boost. Moreover, rORFV induced antigen-specific CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.